Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)

CUSIP: 00461U105

Q4 2022 13F Holders as of 31 Dec 2022

Holder snapshot 7 signals
Share change
-161,686
Put/Call ratio
111%
SEC-reported price per share
$15.75
Number of holders
126
Value change
-$2,542,115
Number of buys
56
Open additional details 1 more signal available
Number of sells
44
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
145,924,870

Security key

00461U105

Report period

Q4 2022

Institutions

126

Top holders

10

Ownership snapshot

Top reported holders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Foresite Capital Manageme...
Disclosed value leader
BlackRock Finance, Inc.
Comparable rows
0/15
Latest evidence
30 Sep 2022
3/4/5 13F Highest disclosed value: $75,714,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

BlackRock Finance, Inc. has the largest disclosed position value at $75.71M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock Finance, Inc.'s linked filing trail.
Disclosed position value Top 5
Foresite Capital Management III, LLC $8.7K
BlackRock Finance, Inc. $75.71M
Venrock Adviser, LLC $71.84M
RA CAPITAL MANAGEMENT, L.P. $69.23M
BVF INC/IL $62.59M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Foresite Capital Management III, LLC
3/4/5
10%+ Owner
—
denominator unverified
$8,690
8,276 shares
— 01 Nov 2021
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$75,714,000
4,810,298 shares
— 30 Sep 2022
Venrock Adviser, LLC
13F
Company
13F
—
denominator unverified
$71,837,000
4,563,962 shares
— 30 Sep 2022
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$69,231,000
4,398,453 shares
— 30 Sep 2022
BVF INC/IL
13F
Company
13F
—
denominator unverified
$62,591,000
3,976,543 shares
— 30 Sep 2022
Rock Springs Capital Management LP
13F
Company
13F
—
denominator unverified
$62,350,000
3,961,249 shares
— 30 Sep 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
126
Shares
65,900,596
Rows available
126
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q3 2025 Across Filers

Q3 2025 holders
103
Q4 2022 holders
126
Holder diff
23
Investor Q3 2025 Shares Q4 2022 Shares Share Diff Share Chg % Q3 2025 value Q4 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .